SAB Biotherapeutics, Inc. Quarterly Operating Margin in % from Q4 2021 to Q2 2024

Taxonomy & unit
ratio: %
Description
The operating margin measures the profit a company makes on a dollar of sales after accounting for the direct costs involved in earning those revenues.
Summary
SAB Biotherapeutics, Inc. quarterly/annual Operating Margin history and growth rate from Q4 2021 to Q2 2024.
  • SAB Biotherapeutics, Inc. Operating Margin for the quarter ending June 30, 2024 was -1.65K %, a 258% decline year-over-year.
  • SAB Biotherapeutics, Inc. annual Operating Margin for 2023 was -1.7K %, a 1306% decline from 2022.
  • SAB Biotherapeutics, Inc. annual Operating Margin for 2022 was -121 %, a 450% decline from 2021.
  • SAB Biotherapeutics, Inc. annual Operating Margin for 2021 was -22 %, a 159% decline from 2020.
Operating Margin, Quarterly (%)
Operating Margin, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Start Date End Date
Q2 2024 -1.65K -1.19K -258% Apr 1, 2024 Jun 30, 2024
Q1 2024 -1.62K -1.38K -592% Jan 1, 2024 Mar 31, 2024
Q4 2023 -1.7K -1.58K -1306% Oct 1, 2023 Dec 31, 2023
Q3 2023 -661 -574 -663% Jul 1, 2023 Sep 30, 2023
Q2 2023 -460 -404 -722% Apr 1, 2023 Jun 30, 2023
Q1 2023 -233 -196 -522% Jan 1, 2023 Mar 31, 2023
Q4 2022 -121 -99 -450% Oct 1, 2022 Dec 31, 2022
Q3 2022 -86.6 Jul 1, 2022 Sep 30, 2022
Q2 2022 -56 Apr 1, 2022 Jun 30, 2022
Q1 2022 -37.5 Jan 1, 2022 Mar 31, 2022
Q4 2021 -22 Oct 1, 2021 Dec 31, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.